Adalimumab for steroid sparing in patients with giant-cell arteritis: Results of a multicentre randomised controlled trial

Annals of the Rheumatic Diseases

Volumn 73, Issue 12, 2014, Pages 2074-2081

  Seror, Raphaèle ^a   Baron, Gabriel ^b   Hachulla, Eric ^c   Debandt, Michel ^d   Larroche, Claire ^e   Puéchal, Xavier ^f,g   Maurier, François ^h   De Wazieres, Benoǐt ⁱ   Quéméneur, Thomas ^j   Ravaud, Philippe ^b   Mariette, Xavier ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔTEL DIEU   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE FORT DE FRANCE   (France)

^e AVICENNE HOSPITAL   (France)

^f CENTRE HOSPITALIER DU MANS   (France)

^g Paris Descartes University ^*  (France)

^h HP Metz Site HSB ^*  (France)

ⁱ NÎMES UNIVERSITY HOSPITAL   (France)

^j CENTRE HOSPITALIER DE VALENCIENNES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; PLACEBO; PREDNISONE; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

AGED; ARTICLE; BREAST CANCER; COLITIS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GIANT CELL ARTERITIS; HERPES ZOSTER; HUMAN; INTENTION TO TREAT ANALYSIS; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; REMISSION; SEPTIC SHOCK; TREATMENT OUTCOME; CLINICAL TRIAL; DRUG COMBINATION; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GIANT CELL ARTERITIS; HUMANS; MALE; PREDNISONE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84922221358     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203586     Document Type: Article

References (32)

1. Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261-71.
2. Gabriel SE, Sunku J, Salvarani C, et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997;40:1873-8.
3. Proven A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003;49:703-8.
4. Nesher G, Sonnenblick M, Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 1994;21:1283-6.
5. Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007;56:2789-97.
6. Hernandez-Garcia C, Soriano C, Morado C, et al. Methotrexate treatment in the management of giant cell arteritis. Scand J Rheumatol 1994;23:295-8.
7. Schaufelberger C, Andersson R, Nordborg E. No additive effect of cyclosporin A compared with glucocorticoid treatment alone in giant cell arteritis: results of an open, controlled, randomized study. Br J Rheumatol 1998;37:464-5.
8. Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002;46:1309-18.
9. De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986;45:136-8.
10. Field M, Cook A, Gallagher G. Immuno-localisation of tumour necrosis factor and its receptors in temporal arteritis. Rheumatol Int 1997;17:113-18.
11. Airo P, Antonioli CM, Vianelli M, et al. Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford) 2002;41:347-9.
12. Cantini F, Niccoli L, Salvarani C, et al. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001;44:2933-5.
13. Ahmed MM, Mubashir E, Hayat S, et al. Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol 2007;26:1353-5.
14. Andonopoulos AP, Meimaris N, Daoussis D, et al. Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 2003;62:1116.
15. Tan AL, Holdsworth J, Pease C, et al. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 2003;62:373-4.
16. Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008;67:625-30.
17. Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007;146:621-30.
18. Baughman RP, Lower EE, Bradley DA, et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005;128:1062-47.
19. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94.
20. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-61.
21. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-26.
22. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122-8.
23. Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004;50:1332-7.
24. Martinez-Lado L, Calvino-Diaz C, Pineiro A, et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore) 2011;90:186-93.
25. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009;68:318-23.
26. Hernandez-Rodriguez J, Segarra M, Vilardell C, et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 2004;43:294-301.
27. Garcia-Martinez A, Hernandez-Rodriguez J, Espigol-Frigole G, et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term follow up of patients with giant cell arteritis. Arthritis Care Res (Hoboken) 2010;62:835-41.
28. Emilie D, Liozon E, Crevon MC, et al. Production of interleukin 6 by granulomas of giant cell arteritis. Hum Immunol 1994;39:17-24.
29. Weyand CM, Fulbright JW, Hunder GG, et al. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000;43:1041-8.
30. Sciascia S, Rossi D, Roccatello D. Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis. J Rheumatol 2011;38:2080-1.
31. Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 2012;64:1720-9.
32. Salvarani C, Magnani L, Catanoso M, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012;51:151-6.